Global Information
회사소개 | 문의

중증 근무력증 : 파이프라인 리뷰

Myasthenia Gravis - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 200977
페이지 정보 영문 152 Pages
가격
US $ 2,000 ₩ 2,274,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,549,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,824,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


중증 근무력증 : 파이프라인 리뷰 Myasthenia Gravis - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 152 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

중증 근무력증은 말초신경의 자기면역성 신경근장애로, 니코틴성 아세틸콜린(ACh) 시냅스 후 수용체에 대한 항체에 의해 근력 저하와 역피로감이 발생하는 난치병입니다. 근력 저하로 인해 호흡 곤란, 씹기·삼킴 곤란, 두부하수, 안면근 취약화, 쉰 목소리, 복시, 안검하수 등이 발병합니다. 치료 옵션으로 자기면역반응을 억제하는 의약품, 면역글로블린 정맥 주입 등을 들 수 있습니다.

세계 각국에서의 중증 근무력증(Myasthenia Gravis) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 각 임상시험 단계 제품 목록, 주요 기업 개요, 주요 치료제 개요(제품 개요, 작용기전, 연구 개발(R&D) 진전 상황), 최신 업계 동향 등의 조사 결과를 전해드립니다.

서론

  • 분석 범위

중증 근무력증 개요

치료제 개발

  • 중증 근무력증용 파이프라인 제품 : 개요
  • 중증 근무력증용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 중증 근무력증 치료제

대학/연구기관에서 연구중인 중증 근무력증 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품

중증 근무력증 치료제 : 개발중인 제품 목록(기업별)

중증 근무력증 치료제 : 연구중인 제품 목록(대학/연구기관별)

중증 근무력증 치료제 개발에 참여하고 있는 기업

  • Achillion Pharmaceuticals, Inc.
  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • arGEN-X BV
  • Baxalta Incorporated
  • Biokine Therapeutics Ltd.
  • BioMarin Pharmaceutical Inc.
  • CuraVac, Inc.
  • GlaxoSmithKline Plc
  • Grifols, S.A.
  • HanAll Biopharma Co., Ltd.
  • Karus Therapeutics Limited
  • Lead Discovery Center GmbH
  • Neurotune AG
  • Novartis AG
  • Pfizer Inc.
  • ReceptoPharm, Inc.
  • Regenesance BV
  • Toleranzia AB

중증 근무력증 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 방법별
  • 분자종류별

치료제 개요

  • amifampridine phosphate
  • ARGX-113
  • BB-008
  • belimumab
  • BKT-130
  • CFZ-533
  • Coversin
  • CVMG-01
  • eculizumab
  • GL-2045
  • HL-161
  • immune globulin(human)
  • KA-1463
  • Monoclonal Antibody to Inhibit C1q for Myasthenia Gravis
  • NT-1654
  • Recombinant Protein for Myasthenia Gravis
  • regenemab
  • RPI-78M
  • SM-201
  • Small Molecule to Inhibit Immunoproteasome Subunit LMP7 for Autoimmune Disorders and Viral Infections
  • Small Molecules to Inhibit Complement Factor D for Myasthenia Grav
  • Vaccine for Myasthenia Gravi

중증 근무력증 치료제 : 최신 파이프라인 동향

중증 근무력증 치료제 : 개발 휴지 상태인 제품

중증 근무력증 치료제 : 개발이 중지된 제품

중증 근무력증 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향 및 프레스 릴리스

부록

도표

LSH 16.04.04

List of Tables

  • Number of Products under Development for Myasthenia Gravis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H1 2019
  • Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Argenx SE, H1 2019
  • Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Myasthenia Gravis - Pipeline by CuraVac Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Grifols SA, H1 2019
  • Myasthenia Gravis - Pipeline by GT Biopharma Inc, H1 2019
  • Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H1 2019
  • Myasthenia Gravis - Pipeline by Momenta Pharmaceuticals Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Neurotune AG, H1 2019
  • Myasthenia Gravis - Pipeline by Novartis AG, H1 2019
  • Myasthenia Gravis - Pipeline by Pfizer Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Protalex Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2019
  • Myasthenia Gravis - Pipeline by Tolerion Inc, H1 2019
  • Myasthenia Gravis - Pipeline by UCB SA, H1 2019
  • Myasthenia Gravis - Dormant Projects, H1 2019
  • Myasthenia Gravis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Myasthenia Gravis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H1 2019, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 5, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Myasthenia Gravis - Overview
  • Myasthenia Gravis - Therapeutics Development
  • Myasthenia Gravis - Therapeutics Assessment
  • Myasthenia Gravis - Companies Involved in Therapeutics Development
  • Myasthenia Gravis - Drug Profiles
  • Myasthenia Gravis - Dormant Projects
  • Myasthenia Gravis - Discontinued Products
  • Myasthenia Gravis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research